Search

Your search keyword '"Ramji, Alnoor"' showing total 427 results

Search Constraints

Start Over You searched for: Author "Ramji, Alnoor" Remove constraint Author: "Ramji, Alnoor"
427 results on '"Ramji, Alnoor"'

Search Results

1. Velacur ACE outperforms FibroScan CAP for diagnosis of MASLD.

3. Association of hepatitis B virus treatment with all-cause and liver-related mortality among individuals with HBV and cirrhosis: a population-based cohort study

5. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

6. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

7. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

8. A global research priority agenda to advance public health responses to fatty liver disease

9. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

10. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study

11. WED-429 Hepatitis B virus care cascade in Rwanda: a population basedstudy

12. WED-495 The impact of integration and decentralization of HBV services on enhancing the HBV care continuum: an interrupted time series

13. OS-058 Disparities in hepatocellular carcinoma survival among people with hepatitis B or hepatitis C virus infection in Canada

14. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

15. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection

17. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

20. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

21. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

27. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

28. O- 23 STRATEGIES TO ELIMINATE HEPATITIS C VIRUS INFECTION IN THE AMERICAS

29. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study

31. Strategies to eliminate hepatitis C virus infection in the Americas

33. Ethnic disparity in mortality related to extrahepatic manifestations among people with chronic HCV infection: a large, linked administrative population-based study in British Columbia, Canada

34. Assessment of clinical and patient reported outcome measures in individuals with chronic hepatitis B who clear HBsAg, followed by the Canadian hepatitis B network

35. The impact of Covid-19 on hepatocellular carcinoma screening in British Columbia

37. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

40. Effect of HBV Treatment on All-Cause and Liver-Related Death Among Individuals with HBV and Cirrhosis in British Columbia

41. Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

42. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study

43. Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA)

44. Impact of Hepatitis B Virus Infection, Non-alcoholic Fatty Liver Disease, and Hepatitis C Virus Co-infection on Liver-Related Death among People Tested for Hepatitis B Virus in British Columbia: Results from a Large Longitudinal Population-Based Cohort Study

45. Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders

46. A phase 2, open‐label, randomized, multiple‐dose study evaluating Inarigivir in treatment‐naïve patients with chronic hepatitis B

47. Chronic hepatitis C infection is associated with higher incidence of extrahepatic cancers in a Canadian population based cohort

49. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver

50. Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

Catalog

Books, media, physical & digital resources